Compumedics Ltd (ASX:CMP)

Company Profile

We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.

In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.

Compumedics Ltd (ASX:CMP)

Company

Website

Sector

Industry

Code

Company Profile

News Coverage

October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’

September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut

Alive and Kicking: ‘We are not alone in going through a lull in markets’, says Clinuvel chair

Market Highlights: Analysts see Nvidia as good pick up, and why investors will be on edge tonight

August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’

Wake Up! Don’t get caught sleeping on these three dreamy stocks

July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month

Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners

Closing Bell: This ASX looks ready to cut its own records after latest Wall Street highs

ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

CLOSING BELL: Big Coal fires up the Energy sector, but not enough to stop the rot

Closing Bell: A very hot ASX banks on big banks after big central banks start cutting

ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

With FDA approval close, Echo IQ’s AI platform is set to disrupt US heart disease market

ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Hot Money Monday: This is what the Father of Momentum Investing thought about ‘undervalued’ stocks

Hot Money Monday: ASX is best place in the world to profit from momentum strategy, says this fundie

Closing Bell: ASX ends it like Beckham… lower and with a pretty whimper, which could still suggest good things ahead

Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Closing Bell: Australian stocks go higher, for longer on bets The Fed won’t have to

Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

CLOSING BELL: ASX sinks to -1.4pc, despite a late tech rally and some sunny Small Caps news

Closing Bell: Local markets shed 0.6pc as we brace for tonight’s US Fed call

Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Check Up: Australian biotech sector continues to be a magnet for US investors

Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight

Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Top 10 at 10: These ASX seafood, copper and rare earths stocks are getting snapped up in early trade

Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Closing Bell: ASX drops 0.41%, RBA predicts more interest rate rises next year

How out of favour Biotech has a PR problem and could learn from Dr Karl

Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

Market Highlights: US inflation and 5 ASX small caps to watch on Thursday

Closing Bell: Volatile? The ASX 200 has criss-crossed its opening level for the 17th time today. (So that’s a yes)

Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

Closing Bell: Galileo digging all the right holes today; big miners, not so much

Closing Bell: Tech on sale as risk assets start to look a lot like riskier assets

Closing Bell: Local markets cope pretty well with Wall Street bleed

Check Up: Money managers are still bullish on Healthcare; here’s what they said

Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month

Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX

ASX Tech Stocks: Data3 gains on results forecast, while resignations & appointments mark the new year

Closing Bell: Gains across the small cap space as the ASX edges higher

ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military

Compumedics secures record sale orders for first half of financial year, inks second MEG sale to Tianjin Normal University

Market Highlights and 5 ASX Small Caps to watch on Wednesday

Closing Bell: ASX limps into the close while a post-COVID ‘meme stonk’ roars higher

Closing Bell: ASX treads water while an IPO dips on debut

Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc

Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment

Compumedics creates local jobs with wearable medtech device

Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Compumedics full-year results highlight improvement in revenue performance

Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

Compumedics Ltd shares reasons why investors should consider the stock at Proactive Lifesciences Webinar

September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut